Industry Focus Transcripts

Here’s an interview with our resident cryptocurrency expert, as well as the latest from around the financial sector.

More and more people are shorting tech giants like Apple and Tesla, but the numbers aren't necessarily cause for concern.

What investors need to know about the multitrillion-dollar U.S. shipping industry, and the many extremely varied subsectors within it.

Schlumberger and Halliburton have trailed the market in the last few years, but it would not be wise to ignore their long-term potential.

An Alexa-enabled microwave might make more sense than you’d initially think, while Apple’s Watch steals the show.

The unicorn debut will offer the market an opportunity to invest in a fast-growing space.

These hidden gems found a niche for themselves and rocked it, and they’re just getting started.

Rumors suggest that a dividend cut might be imminent, but management has other ideas about that.

Summer may not be the best time to own stocks historically, but embracing this old Wall Street adage is far from riskless.

Last week we showered Activision, Take-Two, and EA with love, but what about pure-play mobile game publishers like Zynga and Glu Mobile? Do they deserve a spot on your watch list?

In its last private funding round, Blue Apron reached a valuation of over $2 billion. Now, the company has its sights set on the public market. I dig into the IPO filing to break down the financials and business model for investors.

Citizens Financial became the biggest bank stock IPO in history when it went public in 2014. Since then, it's orchestrated an impressive turnaround.

For the world's most famous beverage company, coffee remains a blank space on its resume.

Major acquisition talks make headlines as American Eagle pursues its apparel rival Abercrombie & Fitch, and Kraft-Heinz eyes a mega-deal with Colgate-Palmolive.

Here’s a look at the three leading person-to-person payment apps and where they could be heading.

The companies have found themselves in the crosshairs of major investors looking to take their restaurant chains private.

A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.

Donald Trump is making headway on removing America from the Paris climate agreement. Here’s what might change and what might stay the same.

Here's what investors need to know about the latest interest rate increase, predictions of a major recession, and more.

Opportunities ahead could make it the perfect time to add these biotechs to your portfolio.